Changing the
Rules of
Biopharma
Discovery
About Us
About Us
Medera strives to eradicate difficult-to-treat and incurable cardiovascular diseases using gene and cell therapies, human mini-organs and other state-of-the-art technologies pioneered by our portfolio companies and partners
Founded in 2014, Novoheart has the longest history in commercializing human cardiac tissue engineering for disease modeling and drug screening. Our founders were among the first-generation biomedical engineers who started the fields back in the late 90s. Novoheart has the industry’s most sophisticated and comprehensive human cardiac tissue engineering platform and the only Human-Heart-in-a-Jar.
Novoheart was previously dually publicly-listed on the Toronto Stock Exchange and Frankfurt Stock Exchange before its acquisition and privatisation by the Medera group in 2020.
Founded in 2019 by the scientific pioneers who started the fields of Cardiac Gene Therapy over three decades ago at the Massachusetts General Hospital of Harvard University, Sardocor is a fully owned subsidiary of the Medera Group.
Sardocor is dedicated to the clinical development of novel therapies for patients with incurable diseases. With three ongoing gene therapy clinical trials for Heart Failure with preserved Ejection Fraction (HFpEF), Heart Failure with reduced Ejection Fraction (HFrEF) and Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD-CM), Sardocor is currently second to none in terms of the number of FDA Investigational New Drug (IND) approvals and the clinical stage maturity.